Acute behavioral changes and long-term antidepressant response can be reliably elicited by surgically targeting and stimulating the subcallosal cingulate (SCC) gyrus area 25, a brain area implicated in depression. While the clinical effectiveness of DBS over the course of six months of treatment has been repeatedly demonstrated, there are differences in the timeline of recovery across different patients. A new study identifies an electrophysiological biomarker that can help optimize this experimental procedure in treating treatment-resistant depression and gain insights into the mechanisms underlying the efficacy of deep brain stimulation.
A new way of treating major depression has been developed by scientists at the University of California San Francisco (UCSF). The approach builds on earlier work that identified signature electrical activities in the brain that correlate to different moods, and brain regions that when stimulated relieve depression. In the new two-step method, the researchers identify a symptom-specific neural biomarker and a treatment location where focal electrical stimulation improves the symptoms. They then implant a device in the identified location, capable of sensing and stimulating electrical impulses that triggers therapeutic deep brain stimulation when the severity of the symptom increases.